Vaxart, Inc. (VXRT)
NASDAQ$0.5497+0.03 (5.80%)
Market Cap
$117.65M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
381 of 924
Rank in Industry
223 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
VXRT Insider Trading Activity
VXRT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $13,578 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Watson W. Mark | director | 1 | $13,578 | 0 | $0 | $13,578 |
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, …
Insider Activity of Vaxart, Inc.
Over the last 12 months, insiders at Vaxart, Inc. have bought $13,578 and sold $0 worth of Vaxart, Inc. stock.
On average, over the past 5 years, insiders at Vaxart, Inc. have bought $22,409 and sold $162.77M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Watson W. Mark (director) — $13,578.
The last purchase of 20,000 shares for transaction amount of $13,578 was made by Watson W. Mark (director) on 2024‑06‑18.
List of Insider Buy and Sell Transactions, Vaxart, Inc.
| 2024-06-18 | Watson W. Mark | director | 20,000 0.01% | $0.68 | $13,578 | +4.46% | ||
| 2022-12-28 | Watson W. Mark | director | 20,000 0.0152% | $0.76 | $15,140 | -1.28% | ||
| 2022-06-22 | Ahmad Fuad | Interim CFO | 5,000 0.0037% | $3.22 | $16,100 | -64.14% | ||
| 2022-01-10 | Sale | Yedid Robert A. | director | 1,500 0.0012% | $6.01 | $9,015 | -42.60% | |
| 2021-11-30 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 3,602 0.003% | $8.00 | $28,816 | -52.20% | |
| 2021-09-10 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,801 0.0015% | $9.10 | $16,389 | -45.32% | |
| 2021-08-10 | Sale | Tucker Sean | SVP, Chief Scientific Officer | 10,000 0.0089% | $10.20 | $102,000 | -45.30% | |
| 2021-08-10 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,801 0.0016% | $10.00 | $18,010 | -45.30% | |
| 2021-07-19 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,800 0.0015% | $8.00 | $14,400 | -29.40% | |
| 2021-06-11 | Sale | Yedid Robert A. | director | 10,000 0.0081% | $8.61 | $86,109 | -24.14% | |
| 2021-06-11 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 1,802 0.0014% | $8.00 | $14,416 | -24.14% | |
| 2021-06-09 | Sale | Echerd Margaret | SVP, Principal Accntng Officer | 47,555 0.0412% | $8.00 | $380,440 | -12.70% | |
| 2021-05-07 | Sale | Latour Wouter | director | 100,000 0.0819% | $7.13 | $712,750 | -6.18% | |
| 2021-05-06 | Sale | Latour Wouter | director | 100,000 0.078% | $6.54 | $653,890 | -2.45% | |
| 2021-03-04 | Sale | Latour Wouter | director | 150,000 0.1327% | $6.04 | $906,450 | +16.22% | |
| 2020-11-23 | Sale | Latour Wouter | director | 333,334 0.2702% | $6.32 | $2.11M | +1.05% | |
| 2020-06-29 | Sale | ARMISTICE CAPITAL, LLC | director | 9.39M 13.9107% | $8.29 | $77.8M | -6.34% | |
| 2020-06-26 | Sale | ARMISTICE CAPITAL, LLC | director | 18.23M 31.5118% | $10.38 | $189.19M | -12.81% | |
| 2020-06-03 | Sale | ARMISTICE CAPITAL, LLC | director | 400,000 0.5415% | $2.77 | $1.11M | +150.91% | |
| 2020-06-02 | Sale | ARMISTICE CAPITAL, LLC | director | 800,000 1.0089% | $2.75 | $2.2M | +135.10% |
Total: 162
*Gray background shows transactions not older than one year
Insider Historical Profitability
123.58%
| Watson W. Mark | director | 78125 0.0343% | $40,406.25 | 2 | 0 | <0.0001% |
| Third Point LLC | other | 6890000 3.0288% | $3.56M | 4 | 1 | <0.0001% |
| Finney Michael J. | director | 452572 0.199% | $234,070.24 | 3 | 0 | <0.0001% |
| FAHIM RAAFAT E F | President, CEO and CFO | 373474 0.1642% | $193,160.72 | 3 | 3 | +50% |
| ARMISTICE CAPITAL, LLC | director | 145523 0.064% | $75,264.50 | 9 | 24 | +502.07% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $110.08M | |
$30,470,407 | 140 | 20.39% | $126.08M | |
$22,597,521 | 91 | 4.59% | $109.66M | |
$860,541,348 | 82 | -5.10% | $129.05M | |
$54,751,750 | 62 | -1.03% | $114.62M |
VXRT Institutional Investors: Active Positions
| Increased Positions | 36 | +29.27% | 2M | +6.31% |
| Decreased Positions | 44 | -35.77% | 4M | -10.7% |
| New Positions | 13 | New | 885,928 | New |
| Sold Out Positions | 19 | Sold Out | 632,186 | Sold Out |
| Total Postitions | 115 | -6.5% | 36M | -4.38% |
VXRT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Sio Capital Management, Llc | $5,861.00 | 5.07% | 11.52M | -2M | -15.38% | 2024-12-31 |
| Vanguard Group Inc | $5,129.00 | 4.44% | 10.08M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $1,522.00 | 1.32% | 2.99M | -978,449 | -24.65% | 2024-12-31 |
| Geode Capital Management, Llc | $1,324.00 | 1.15% | 2.6M | +57,911 | +2.28% | 2024-12-31 |
| Blackrock, Inc. | $1,018.00 | 0.88% | 2M | +225,438 | +12.71% | 2024-12-31 |
| Silverarc Capital Management, Llc | $549.00 | 0.48% | 1.08M | +77,782 | +7.78% | 2024-12-31 |
| State Street Corp | $351.00 | 0.3% | 688,845 | +94,700 | +15.94% | 2024-12-31 |
| Squarepoint Ops Llc | $263.00 | 0.23% | 516,798 | +251,789 | +95.01% | 2024-12-31 |
| Citadel Advisors Llc | $255.00 | 0.22% | 501,623 | +501,623 | New | 2024-12-31 |
| Ubs Group Ag | $252.00 | 0.22% | 495,793 | +495,475 | +155,809.75% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.